Global UDI Compliance 2026: Complete Deadlines Guide by Country (EU, US, Switzerland, Australia, China, Brazil, Singapore)

2026 Is the Year Global UDI Compliance Becomes Unavoidable

For years, Unique Device Identification (UDI) has been a regulatory requirement that many manufacturers could defer. The US FDA's GUDID database has been operational since 2015, but EU EUDAMED was perpetually delayed, and many countries had no UDI system at all. That era is over.

In 2026, mandatory UDI compliance deadlines are converging across at least seven regulatory jurisdictions simultaneously:

• European Union: EUDAMED UDI/Device module becomes mandatory May 28, 2026
• Switzerland: swissdamed Product Module becomes mandatory July 1, 2026
• Australia: AusUDID first phase (Class III and IIb) becomes mandatory July 1, 2026
• China: NMPA expanding UDI to Class II devices by June 1, 2027 (announcement March 2026)
• Brazil: ANVISA UDI requirements for Class III devices effective January 2026
• Singapore: SMDR Class C device compliance by November 1, 2026
• United States: QMSR alignment makes UDI data consistency an inspection priority from February 2026

For manufacturers operating across multiple markets, this creates an unprecedented data submission, maintenance, and lifecycle management challenge. Each regulatory system has unique data structures, submission requirements, and timelines. Yet your product data must remain consistent across all of them.

This guide provides a complete country-by-country breakdown of UDI compliance deadlines, data requirements, and practical preparation steps.

What Is UDI and Why Does It Matter

A Unique Device Identifier (UDI) is a unique numeric or alphanumeric code that identifies a medical device on its label and packaging. The UDI consists of two parts:

• UDI-DI (Device Identifier): Identifies the specific device model/version. This is typically the GTIN, UPC, or other product identifier assigned by an issuing entity.
• UDI-PI (Production Identifier): Identifies the unit of production, such as lot/batch number, serial number, expiration date, or manufacturing date.

The UDI system serves three regulatory purposes:

1. Traceability: Enables tracking of devices from manufacture through distribution to patient use, supporting recall management and adverse event reporting
2. Transparency: Provides regulators, healthcare providers, and patients with structured, searchable device information through public databases
3. Post-market surveillance: Links device identity to safety reports, clinical outcomes, and real-world evidence across the product lifecycle

Country-by-Country UDI Deadlines and Requirements

European Union: EUDAMED (May 28, 2026)

The European Commission published Implementing Decision (EU) 2025/2371 on November 27, 2025, confirming that the first four EUDAMED modules are fully functional. This triggered a six-month transition period ending on May 28, 2026, when the following modules become mandatory:

1. Actor Registration (all economic operators must obtain an SRN)
2. UDI/Device Registration (all devices must be registered at the UDI-DI level)
3. Notified Bodies & Certificates (certificate data uploaded by NBs)
4. Market Surveillance

Key Deadlines

Data Requirements for UDI/Device Registration

• Basic UDI-DI (BUDI-DI): Groups devices with same intended purpose, risk class, and design characteristics
• UDI-DI: GTIN or equivalent on the device package
• Risk class and classification rule applied
• Storage and handling conditions
• Critical warnings and contraindications
• Catalogue number
• EMDN (European Medical Device Nomenclature) code
• Intended purpose (must match labeling and technical documentation exactly)
• CMR substance declarations
• Labeling language information

Consequences of Non-Compliance

Devices not registered in EUDAMED after the mandatory date cannot be legally placed on the EU market. Distributors and hospitals will be able to check the database in real time. If your device is not there, they cannot purchase it. Competent authorities may impose market withdrawal, fines, and in severe cases, criminal liability.

United States: FDA GUDID (Ongoing, QMSR Impact from February 2026)

The US has the most mature UDI system. GUDID (Global Unique Device Identification Database) has been operational since 2015, and class-by-class UDI labeling requirements have been phased in over the past decade.

QMSR Inspection Impact (New in 2026)

The FDA's updated compliance program (CP 7382.850) now uses a Total Product Life Cycle (TPLC) approach to inspections. During an audit, inspectors trace UDI data from design and manufacturing through to post-market surveillance. Key requirements for 2026:

• UDI registration data in GUDID must be consistent with actual product labeling
• Inconsistencies can result in a "misbranded" or "adulterated" device charge
• GUDID data updates must be made within 30 days of any change to device information
• Direct marking requirements apply to reusable devices in applicable classes

Switzerland: swissdamed (July 1, 2026)

Swissmedic activated the swissdamed UDI Devices module in August 2025 for voluntary submissions. Mandatory registration begins July 1, 2026. The system aligns closely with EUDAMED standards.

Key Deadlines

Unique Aspects

• Swiss CH REP is required for foreign manufacturers (similar to EU Authorized Representative)
• Device registration fees are expected to begin January 2027 (exact fees pending)
• Machine-to-Machine (M2M) registration functionality became available by end of March 2026

Australia: AusUDID (July 1, 2026)

The Australian Therapeutic Goods Administration (TGA) implemented UDI requirements through an amendment to the Therapeutic Goods Regulations 2002, effective March 24, 2025. Implementation is phased by device risk class.

Phased Implementation Timeline

Key Requirements

• UDI must be on device labels and all relevant packaging levels in both human-readable and machine-readable (barcode) format
• UDI data must be submitted to the Australian UDI Database (AusUDID)
• The Sponsor (Australian entity) is responsible for data accuracy in AusUDID and ARTG entries
• The Manufacturer is responsible for correct UDI identifier assignment
• TGA published UDI Guide V2.0 in February 2026 with updated operational guidance

China: NMPA UDI Database (June 1, 2027 for Class II)

China's NMPA, together with the National Health Commission and National Healthcare Security Administration, issued Announcement No. 21 of 2026 on March 13, 2026, confirming the final phase of China's nationwide UDI rollout. Announcement No. 15 of 2026 clarifies exemption scenarios.

Implementation Timeline

Key Requirements

• UDI data must be uploaded to the national UDI database before market launch
• UDI information must be included in all registration, filing, renewal, and modification submissions
• Products manufactured before implementation dates may continue to be marketed without UDI
• UDI data submission is not part of the registration technical review
• Changes to identifiers do not trigger formal variation procedures
• UDI is linked to reimbursement and healthcare data systems

Exemptions

Custom-made medical devices and products intended solely for research use may be exempt under Announcement No. 15 of 2026. Manufacturers must assess eligibility and maintain supporting documentation.

Brazil: ANVISA (January 2026 Onward)

Brazil's UDI system (Sistema Integrado de Identificacao de Dispositivos) is being phased in by device class:

Singapore: SMDR (November 1, 2026 for Class C)

Singapore's Medical Device Register (SMDR) requires UDI compliance phased by device class:

South Korea: MFDS UDI

South Korea has a fully operational UDI system with class-based compliance dates:

Colombia: INVIMA UDI (In Development)

Colombia is developing UDI requirements as part of its broader medical device regulatory modernization. While specific implementation dates are still being finalized, INVIMA has indicated alignment with the IMDRF UDI framework. Manufacturers should monitor INVIMA communications for formal timeline announcements.

India: CDSCO UDI (Pending)

India's Medical Devices Rules, 2017 (Rule 46) were set to require UDI labeling by January 1, 2022. However, detailed implementation guidance has not yet been released. Manufacturers must currently meet CDSCO's labeling and traceability requirements as published, but a formal UDI database has not been established.

Cross-Country Comparison: All Active UDI Deadlines in 2026

Practical Preparation: What Manufacturers Must Do Now

Step 1: Audit Your Global Device Portfolio

Map every device you sell across every market. For each device, identify:

• Current UDI-DI and Basic UDI-DI assignment status
• Applicable compliance deadline in each target market
• Data completeness against each database's requirements
• Gap between current labeling and UDI labeling requirements

Step 2: Assign UDIs Through Recognized Issuing Entities

UDI-DIs must be assigned through an FDA-accredited or EU-recognized issuing entity:

• GS1 (GTIN-based, most widely used globally)
• HIBCC (Health Industry Business Communications Council)
• ICCBBA (ISBT 128, primarily for blood and tissue products)
• IFA (Informationsstelle für Arzneispezialitäten, primarily EU)

If you have not yet assigned Basic UDI-DIs for your EU portfolio, this is the critical first step. The Basic UDI-DI is the primary key that groups devices, links to certificates, and connects to vigilance records in EUDAMED.

Step 3: Prepare Structured Data for Each Database

Each UDI database has unique data field requirements. Common elements include:

• Device identifier (UDI-DI and production identifiers)
• Device name and description
• Risk classification
• GMDN or EMDN nomenclature codes
• Intended purpose
• Sterilization status
• Whether the device contains latex, phthalates, or CMR substances
• Labeling language information (EU-specific)
• Manufacturer and authorized representative details

The challenge is maintaining data consistency across databases. Your device description, intended purpose, and classification must match across GUDID, EUDAMED, swissdamed, and any other applicable systems. Mismatches create regulatory exposure.

Step 4: Submit Early to Avoid Last-Minute Bottlenecks

For EUDAMED specifically, competent authorities across EU member states are already experiencing growing registration volumes. Review timelines that were measured in days are stretching to weeks. Submit early to allow time for validation errors, correction cycles, and competent authority review.

For swissdamed, the same dynamic will occur as the July deadline approaches.

Step 5: Establish Ongoing Data Maintenance Processes

UDI registration is not a one-time event. You must maintain and update your data when:

• Device specifications change
• New product variants are added
• Labeling is updated
• Certificates are renewed or modified
• Devices are discontinued

Build UDI data management into your change control process and assign clear ownership for each database.

The Hidden Complexity: Legacy Device Data Migration

Legacy devices present a unique challenge. Because they pre-date the UDI system, they often lack a Basic UDI-DI. EUDAMED requires a "EUDAMED DI" and "EUDAMED ID" for these devices as surrogates for standard UDI identifiers.

Mapping your legacy portfolio to this new structure is a major project. You must:

1. Identify every legacy device still on the EU market
2. Determine its current classification under MDR (which may differ from the old MDD classification)
3. Assign a Basic UDI-DI that correctly groups devices with the same intended purpose
4. Ensure the assigned classification matches the NB certificate and technical documentation
5. Upload all data by November 28, 2026

The same logic applies to swissdamed (January 2027 grace period deadline) and to Australia's phased rollout.

What Happens If You Miss a Deadline

The consequences are severe and escalating:

• EU: Devices cannot be legally placed on the market. Distributors and hospitals will verify registration in real time. Unregistered devices face market withdrawal, fines, and potential criminal liability under MDR Article 83. Additionally, under Article 10a (effective January 2025, introduced by Regulation EU 2024/1860), manufacturers must notify authorities of supply chain disruptions for devices registered as "On the Market" in EUDAMED. Failure to notify may lead to double liability.
• Switzerland: Same as EU, with additional immediate registration trigger if a vigilance event occurs on an unregistered device.
• Australia: TGA may suspend or cancel the device from the ARTG, effectively removing it from the Australian market.
• China: NMPA may reject registrations, deny renewals, or revoke existing approvals.
• US: FDA inspectors will cite UDI inconsistencies as misbranding under 21 CFR Part 801. During QMSR inspections under CP 7382.850, UDI data traceability is now a standard audit element.

Frequently Asked Questions

What is UDI? Unique Device Identification (UDI) is a system for identifying medical devices through a unique code on the device label and packaging. The UDI consists of a Device Identifier (UDI-DI) that identifies the specific device model, and a Production Identifier (UDI-PI) that identifies the production unit (lot, serial number, expiry date).

When does EUDAMED UDI registration become mandatory? May 28, 2026. From this date, all new MDR/IVDR devices must be registered in EUDAMED before being placed on the EU market. Legacy devices already on the market have until November 28, 2026.

What is a Basic UDI-DI? The Basic UDI-DI (BUDI-DI) is the primary key in EUDAMED that groups devices with the same intended purpose, risk class, and essential design characteristics. It links to certificates, vigilance records, and clinical investigations. It is distinct from the UDI-DI, which appears on the device package as the GTIN.

Does Switzerland require separate UDI registration? Yes. Switzerland's swissdamed system becomes mandatory July 1, 2026. It aligns with EUDAMED but is a separate database requiring separate registration.

When does Australia require UDI? Australia's first UDI deadline is July 1, 2026, for Class III and Class IIb medical devices. Implementation continues through 2030, with each phase adding lower-risk device classes.

What happens if a device is not registered in EUDAMED after May 28, 2026? The device cannot be legally sold in the EU. Distributors, hospitals, and competent authorities can verify registration status in real time. Unregistered devices face market withdrawal and potential enforcement action.